AN2 Therapeutics, Inc.
ANTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001880438
In the last 90 days, AN2 Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 66 institutions reported holding it in 13F filings for Q2 2026, worth $119.0M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in AN2 Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- +7 vs. Q3 2024
- Shares held
- 14.5M
- +1.02M (+7.5%) vs. Q3 2024
- Total value
- $20.1M
- +$5.59M (+38.7%) vs. Q3 2024
- New holders
- 13
- 12 more added
- Sold out
- 6
- 7 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 66 | $119.0M |
| Q1 2026 | 52 | $74.8M |
| Q4 2025 | 38 | $9.88M |
| Q3 2025 | 36 | $10.5M |
| Q2 2025 | 37 | $8.78M |
| Q1 2025 | 38 | $19.5M |
| Q4 2024 | 38 | $20.1M |
| Q3 2024 | 31 | $14.5M |
| Q2 2024 | 45 | $41.7M |
| Q1 2024 | 54 | $60.9M |
| Q4 2023 | 51 | $417.9M |
| Q3 2023 | 37 | $320.3M |
| Q2 2023 | 31 | $99.9M |
| Q1 2023 | 38 | $94.8M |
| Q4 2022 | 36 | $92.9M |
| Q3 2022 | 38 | $165.1M |
| Q2 2022 | 36 | $72.4M |
| Q1 2022 | 18 | $134.1M |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding AN2 Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 5,749,432 | $7.93M | 4.93% | 00.0% | Unchanged |
| Almitas Capital LLC | 1,313,111 | $1.81M | 0.40% | +1,313,111 | New |
| Vanguard Group Inc | 1,035,947 | $1.43M | 0.00% | −5,580−0.5% | Reduced |
| Pfizer Inc | 715,295 | $987.1K | 0.04% | +715,295 | New |
| Renaissance Technologies LLC | 579,773 | $800.1K | 0.00% | +155,973+36.8% | Added |
| Peapod Lane Capital LLC | 578,825 | $798.8K | 0.79% | +578,825 | New |
| Two Sigma Advisers, LP | 528,300 | $729.1K | 0.00% | +407,400+337.0% | Added |
| Bank of Montreal | 422,077 | $582.5K | 0.00% | +422,077 | New |
| Two Sigma Investments, LP | 400,332 | $552.5K | 0.00% | +222,492+125.1% | Added |
| Bank of Nova Scotia | 394,868 | $544.9K | 0.00% | +394,868 | New |
| Bank of America Corp | 385,475 | $532.0K | 0.00% | +369,265+2,278.0% | Added |
| Aldebaran Capital, LLC | 343,684 | $474.3K | 0.45% | +243,184+242.0% | Added |
| Adage Capital Partners GP, L.L.C. | 312,615 | $431.4K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 301,421 | $416.0K | 0.00% | +245+0.1% | Added |
| Geode Capital Management, LLC | 227,796 | $314.4K | 0.00% | +7,634+3.5% | Added |
| Millennium Management LLC | 209,366 | $288.9K | 0.00% | −188,559−47.4% | Reduced |
| Stonepine Capital Management, LLC | 196,732 | $271.5K | 0.22% | +196,732 | New |
| UBS Group AG | 170,292 | $235.0K | 0.00% | +170,292 | New |
| Bridgeway Capital Management, LLC | 162,200 | $223.8K | 0.01% | −34,800−17.7% | Reduced |
| State Street Corp | 87,002 | $120.1K | 0.00% | +26,700+44.3% | Added |
| Marquette Asset Management, LLC | 83,206 | $114.8K | 0.02% | +18,703+29.0% | Added |
| Citadel Advisors LLC | 67,994 | $93.8K | 0.00% | +67,994 | New |
| Squarepoint Ops LLC | 62,441 | $86.2K | 0.00% | +62,441 | New |
| Northern Trust Corp | 43,196 | $59.6K | 0.00% | +10,601+32.5% | Added |
| XTX Topco Ltd | 34,179 | $47.2K | 0.00% | +10,520+44.5% | Added |
| Captrust Financial Advisors | 28,667 | $39.6K | 0.00% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 26,900 | $37.1K | 0.00% | −39,200−59.3% | Reduced |
| Integrated Wealth Concepts LLC | 25,000 | $34.5K | 0.00% | 00.0% | Unchanged |
| Private Advisor Group, LLC | 22,500 | $31.1K | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 10,185 | $14.1K | 0.00% | +10,185 | New |
| Federated Hermes, Inc. | 7,492 | $10.3K | 0.00% | +4,486+149.2% | Added |
| Tower Research Capital LLC (TRC) | 1,463 | $2.02K | 0.00% | −2,793−65.6% | Reduced |
| Innovative Advisory Group, LLC | 1,170 | $1.61K | 0.00% | +1,170 | New |
| BNP Paribas Arbitrage, SA | 312 | $431 | 0.00% | +312 | New |
| Morgan Stanley | 300 | $414 | 0.00% | −3−1.0% | Reduced |
| Advisor Group Holdings, Inc. | 300 | $414 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 200 | $276 | 0.00% | +200 | New |
| JPMorgan Chase & Co | 52 | $72 | 0.00% | −2−3.7% | Reduced |
| Ra Capital Management, L.P. | 0 | $0 | 0.00% | −1,999,997−100.0% | Sold out |
| TCG Crossover Management, LLC | 0 | $0 | 0.00% | −1,555,118−100.0% | Sold out |
| Acuitas Investments, LLC | 0 | $0 | 0.00% | −445,783−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −79,359−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −42,335−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |